Chemicals used for the induction of Alzheimer’s disease-like cognitive dysfunctions in rodents

Onesimus Mahdi¹,², Mohamad Taufik Hidayat Baharuldin¹, Nurul Huda Mohd Nor¹, Samaila Musa Chiroma¹,³, Saravanan Jagadeesan¹,⁴, Mohamad Aris Mohd Moklas¹,*

ABSTRACT
Alzheimer’s disease (AD) is the most frequent and multifactorial form of dementia, characterised by multiple cognitive impairments and personality changes. Different methods including chemicals have been used to induce AD-like symptoms in rodent in order to screen many therapeutic drugs for a variety of cognitive dysfunctions. Articles from reliable databases such as Google Scholar, Science Direct, PubMed, Scopus, and Ovid were searched and retrieved with the following descriptors: ‘Alzheimer’s disease’, ‘Cognitive impairments’, ‘Neurotoxins that induce AD’, ‘Alzheimerogenic chemicals’, ‘excitotoxins’, ‘Amyloid beta’, ‘neurofibrillary tangles’. A number of chemicals have been studied to develop an animal model of AD on the basis of their mechanism of action for cognitive dysfunctions. Some of such chemicals are Heavy metals, Scopolamine, Ethanol, Colchicine, Streptozotocin, Lipopolysaccharide, and Okadaic acid among others, with a view to understanding AD pathophysiology including AD causative theories and also highlight some Alzheimerogenic chemicals for the purpose of enriching our existing knowledge. It is worth mentioning that not all the biochemical, histopathological, cognitive and behavioural abnormalities can be recapitulated. Nonetheless, experimental models of AD produced by chemicals offer insights to unravelling the pathogenesis of the disease.

Key words: Alzheimerogenic chemicals, Cognitive dysfunction, Alzheimer’s disease, Alzheimer’s pathogenesis, Amyloid beta

INTRODUCTION
As the aging population is increasing, the rate of age-associated diseases among older adults has become a serious health concern worldwide¹. It is well-established that these age-related diseases cause progressive and irreversible loss of neurons and subsequently lead to dementia. One of such age-related disorders is Alzheimer’s disease (AD). AD, a neurodegenerative disease, is one of the most common and multifactorial forms of dementia characterized by multiple cognitive impairments, personality changes, and abnormal behavior². The key pathological elements observed in AD brain tissues are amyloid beta (Aβ) peptide and hyperphosphorylated tau (p-tau) protein, although the exact mechanisms which cause these alterations are yet to be uncovered³. The formation of Aβ is due to the aggregation of extracellular senile plaques (SP), while neurofibrillary tangles (NFTs) are caused by abnormal deposits of p-tau proteins³. Furthermore, mitochondrial dysfunction, synaptic damage, inflammatory responses, defective neurotransmissions, hormonal alterations and abnormalities in the cell cycle are all linked with AD⁴–⁶. The remarkable risk factors linked with the progression of AD are old age, as well as multiple genetic and environmental factors. Although the etiology of AD remains unclear, multiple findings have revealed that oxidative stress is an early characteristic of the AD pathophysiological process and also involved in the formation of Aβ and NFTs⁷. Thus, several attempts are ongoing in order to establish anti-AD drugs that could target specific pathogenesis, but these have not garnered much success. On the other hand, animal models have been used to trigger pathological changes similar to the human form of AD and to identify the pathogenesis, especially during the pre-symptomatic stage⁸. There is a dearth of knowledge with respect to chemically-induced AD models. Hence, this review is aimed at exploring some of the chemicals that are used for the induction of AD-like pathologies and behavioral deficits.

HISTORY OF AD
AD was first reported by Alois Alzheimer in 1906, but it was not until around 70 years after its discovery that
much interest was placed on AD research. The findings that have emerged have unraveled and demonstrated, importantly, that the effects of AD commence a long time before its symptoms manifest. Several lines of evidence have revealed that AD is a prevailing root of dementia and a significant source of death in the world. Since its discovery, AD has received substantial attention among the types of dementias that are of global health concern, over the years, due to its debilitating nature. To date, the precise etiology of AD remains to be elucidated, as well as questions such as why the disorder and its symptoms advance so quickly in some people (but is delayed in others), and how the disorder could be more effectively managed or treated.

CHARACTERISTICS AND SYMPTOMS OF AD

AD is characterized by loss of memory, mood swings, problems with attention and orientation, and difficulties in carrying out daily activities. The two main pathological hallmarks of AD are aggregations of amyloid plaques (extracellular) formed by $A\beta$ and NFTs (intracellular), produced by the hyperphosphorylation of tau protein. These alterations are ultimately followed by severe damage and loss of neurons in the brain regions concerned with memory and learning. AD is distinguished at the cellular level by mitochondrial dysfunction, oxidative stress, metal imbalance, inflammation, and apoptosis, among other hallmarks.

Furthermore, several symptoms are observed in individuals living with AD which changes over a period of time. Of the symptoms reported, loss of memory in recalling recent conversations are some of the early clinical manifestations; as well, depression and apathy have been identified in AD.

Additionally, other symptoms that appear later in life as the disease progresses include amnesia, disorientation, impaired communication, confusion, poor judgement, difficulty in swallowing, speaking, and walking. These important changes seen in AD patients reflect the severity of neuronal loss in different regions of the brain. There are three stages in AD: early, moderate and severe - through which the symptoms of the disease progress and differ from individual to individual. During the early stage of AD, patients can carry out basic things independently with little assistance for some activities; these activities include driving, walking, and other hobbies that can still be done by the patients. However, during the moderate stage of AD, patients may be unable to carry out routine activities, may become disoriented, and even develop personality disorders and behavioral changes (such as agitation and suspiciousness). Once it reaches the severe stage of AD, the patients become dependent on people in doing daily activities, such as eating, dressing, and bathing, among other activities.

PREVALENCE OF AD

AD is the primary root cause of dementia; as of 2015, around 46.8 million people worldwide suffered from dementia. This number is expected to increase exponentially to reach 131.5 million by 2050 if there are no interventions. In terms of prevalence between genders, AD is more of an old age disease, and women have been reported to have a longer life expectancy when compared to men. Hence, women account for about two-thirds of the elderly population affected by AD. Indeed, AD has a direct economic burden worldwide, with studies indicating that AD management cost 818 billion USD in 2016; in 2018, the expected projected cost rose to 1 trillion USD.

AD CAUSATIVE HYPOTHESES

TAU HYPOTHESIS

The tau hypothesis suggests that hyperphosphorylation of tau protein leads to the conversion of normal tau into the paired helical filament (PHF-tau) and NFTs. Previously, $A\beta$ had been the focus of AD research. Only recently have researchers begun to shift focus to tau protein due to the fact that a variety of reports have shown tau proteins being among the key elements contained in the NFTs. Tau protein, a member of the microtubule-associated protein, is also a functional monomeric and unfolded cell membrane protein, located within the cytosol of a neuron and very crucial in tubulin stabilization. In addition, tau is known to control neurite growth and have a role in axonal guidance, thus enhancing the normal function of neurons. In humans, tau protein is only found in trace levels in non-neuronal cells. Tau goes through various post-translational changes, especially hyperphosphorylation, a process which acts as a significant factor in influencing the stability of microtubules, thereby leading to tau protein accumulation in AD. Previous findings have shown that hyperphosphorylation of tau protein occurs via conformational changes, which are followed by the transformation of tau monomer to tau oligomer, leading to the paired helical filament and NFT formation. Recent studies have revealed that NFT itself does not appear to be implicated in causing neurotoxicity leading to the onset of neurodegeneration, though the
hyperphosphorylated tau that disintegrates to form oligomers (the toxic form of tau) is implicated in neuronal damage. In addition, recent in vivo and in vitro findings in rats have highlighted that tau pathology may have far-reaching effects in distinct brain regions. Tau, a microtubule-associated protein, acts as a scaffolding component to assist in stabilizing microtubules by influencing tubulin stability in order to control the normal neuronal function.

The position of the tau gene, microtubule-associated protein tau (MAPT), is essential and is located on 100 kb of the long arm of human chromosome 17 at locus 17q21, and has 16 exons. Moreover, it has been shown that in the brain of humans, the tau proteins encode six isoforms that have different sizes, with their length range being between 352 and 441 amino acids. These isoforms have some variations, three repeats (3R) or four repeats (4R) in the C-terminal, and also the presence or absence of one (29 amino acids) or two inserts (58 amino acids) in the N-terminal part, which bind to actin proteins and differentiate them. Findings have revealed that the repeat areas (244–268 amino acids) located in the C-terminal are the main domain, which causes the clumping of tau to microtubule. Furthermore, findings have suggested that tau phosphorylation at specific epitopes could adjust the capability of tau to cling to microtubule. Many post-translational changes, mostly tau hyperphosphorylation, were considered to be involved as essential elements that influence the assembly of microtubule which, in turn, cause tau accumulation in AD. Thus, tau protein goes through conformational alterations whereas the transformation of tau monomer to tau oligomer causes the accumulation of tau, thereby causing it to pair with a helical filament and produce NFTs (due to hyperphosphorylation of tau). Emerging studies have revealed that NFTs are not associated with causing neurotoxicity. Nonetheless, the intermediary tau oligomer was reported to be a toxic form of tau that is implicated in synaptic destruction in AD.

Formation of Aβ
Aβ peptide is a derivative of Amyloid β-precursor protein (AβPP), also an intrinsic type I glycoprotein which has a broad ectodomain. The position of the chromosome for AβPP is found on 21q21.2. There are 18 exons in the APP gene that exceeds 170 kb, thereby creating 10 isoforms through discrete splicing. These isoforms measure between 563 and 770 amino acids. APP is 695 amino acids in length and is one of the isoforms that has been previously reported to be found in neurons of the central nervous system. The specific area that codes Aβ-strings is made up of 16 and 17 exons, of which therein are (40 and 43) amino acid residues. Specifically, this area continues from the ectodomain to the protein’s transmembrane domain. APP’s central domain possesses strong affinity; hence, it can bind to ions such as copper (Cu) and Zinc (Zn), as well as heparin and collagen, within the extracellular matrix, thereby mediating the interplay of APP with the extracellular matrix. The sphere implicated in the neuritic process is defined by a precise string which is seen following the inclusion of exon 7 products. APP isoforms have been known to play vital roles in enhancing coordination between cells and, thus, a few of those roles are hereby outlined.
isofform (of 695 amino acid) has been shown to be involved in aiding coordination between cells and enhancing the connection to the extraneuronal matrix, thereby leading to stability. APP within the intracellular domain may be associated with a cytoskeletal system that transports constituents within a particular cell. APP1-671 (βAPPs) and APP1-687 (αAPPs) are the other two APP isoforms produced in segments; they offer a protective role to the neurons and regulate events at the synapse.  

**Processing of APP**

Proteolytic series of events taking place around and in the APP transmembrane sphere yield a better expression for the production of toxic Aβ42 protein, and eventually for AD pathogenesis. Three different divisions release the APP ectodomain from the membrane. These divisions have been confirmed to be α-secretase split (which separates Aβ-domain and inhibits Aβ-development- by generating amyloidogenic substance- due to the incapability of developing pathogenic Aβ), β-secretase cleavage (the segment produced from α-secretase, while the β-secretase segments remains connected to the membrane; following further conversion by γ-secretase it becomes weakened), and Aβ-protein (Aβ42) breakage (whose aggregation is thought to cause AD due to the presence of toxic and fibril aggregates).  

**Biochemistry of Senile Plaques**

Blocq and Marnesco, in 1892, were the first to demonstrate that senile plaques (SP) could be described as densely packed structures called amyloid bodies. The process by which amyloid bodies develop and are implicated in AD development is known as amyloidosis. Fibrillogenic proteins (about 10 nm in diameter; amyloid fibrils that are smooth and straight) and non-fibril components (ApoE and serum Aβ components) are the contents of the amyloid bodies. The SPs, which are also called amyloid plaques, are the product of an extracellular accumulation of Aβ protein.  

**CHOLINERGIC HYPOTHESIS**

The oldest theory among the AD causative theories is the cholinergic hypothesis. This hypothesis states that a decrease in neurotransmitters, known as acetylcholine, in neurons is responsible for AD etiology. The cholinergic hypothesis has been postulated for more than 3 decades now and suggests that abnormal acetylcholine-containing neurons in the basal ganglia are implicated in cognitive decline seen in AD patients. Essentially, acetylcholine (ACh) is a neurotransmitter utilized by cholinergic neurons and is crucial for physiological processes like attention, learning, memory, stress response, wakefulness, and sleep, as well as sensory information. Damage to cholinergic neurons was observed as an important pathological alteration which corresponds with cognitive destruction seen in AD. Consequently, this hypothesis was initially tested using cholinesterase inhibitors which are used for AD treatment. Thus, as a result of the trial, it has been noted that tacrine, one many cholinesterase inhibitors (including donepezil, galantamine, rivastigmine, and memantine), was the earliest anti-AD drug to be used in the clinic. However, due to some identified severe side effects, it has been retrieved from the market since 2012. Even though cholinesterase blockage is a typical palliative treatment with minor gain, presently, it appears to be the only obtainable clinical remedy that offers hope to despairing patients with AD. Despite these facts, the cholinergic hypothesis has not been widely accepted, mainly due to the fact that the medication was proposed to treat deficiency of acetylcholine but was not effective. Nonetheless, about 4 of the 5 approved anti-AD drugs available in the market today were developed based on the cholinergic hypothesis.  

**OXIDATIVE STRESS HYPOTHESIS**

Oxidative stress is believed to be critical in AD pathogenesis. Notably, the brain is known to consume more energy and exert more functions than any other organs during mitochondrial respiration, which also increases the likelihood of reactive oxygen species (ROS) exposure. Furthermore, AD is closely linked to molecular oxidative stress, as well as protein nitration, the rise of protein oxidation, lipid peroxidation, and glycoxidation. Moreover, AD is closely linked to the aggregation of Aβ, which has been reported to cause oxidative stress. Hence, antioxidant compounds are good candidates to offer protection against oxidative stress and Aβ toxicity, to a certain extent. Although oxidative stress is one aspect of AD, the antioxidant approach has been disputed, too, since it lacks the potential to impede the advancement of AD, and has been suggested to be used as part of combination therapy.  

**INFLAMMATION HYPOTHESIS**

Recent studies have uncovered that neuroinflammation and aberrant gliosis are also emblems of AD. Indeed, the inflammation hypothesis has been validated by genetic and transcriptomic studies. Microglia-related pathways were observed as crucial
risk factors for AD and its pathogenesis. A wealth of information has indicated that microglia is a crucial factor. For instance, during the initial phase of AD, microglia and its associated proteins, such as the Triggering Receptor Expressed on Myeloid Cells-2 (TREM2), can influence synaptic reduction. The process of activity-dependent and long-term synaptic plasticity is the typical and intrinsic basis of learning and memory that could be the observable effects on long-term potentiation. Thus, subsequently, amyloid plaques will be surrounded by aberrant microglia and astrocytes, and produce several proinflammatory cytokines. These series of events are the steps involved in the evolution of AD. However, in the clinic, non-steroidal anti-inflammatory drugs (NSAIDS) have not appeared to be beneficial. This could be largely due to the link between innate immunity and the complexity of AD pathogenesis; thus, the immune responses generated could either be detrimental or useful based on the context.

Nonetheless, there are new findings that indicate that the PD-1 immune crossing point barrier decreases the pathology of AD, thereby enhancing memory in AD mouse models, and has become an area for subsequent research. The recent awareness towards uncovering the mechanisms involved regarding microglia disruption in clipping, neurogenesis and plasticity regulation are unlocking areas, allowing for the exploration of better therapeutic interventions and diagnoses of AD. Understanding the abnormal microglial roles and restoring homeostasis could provide a new set of concepts for treating AD. However, due to the intricacy and distinct roles of microglia in health and disease, new biomarkers that reflect the functions of specific microglia are critically needed.

Despite all the above armamentarium, AD still needs to be properly understood in order to address its remote causes and the mechanisms underlying its progression, of which chemicals or drugs have been indicated as some of the causative factors.

**MITOCHONDRIAL CASCADE HYPOTHESIS**

Swerdlow was the first person to propose the mitochondrial cascade theory in 2004, where he posits that mitochondrial abnormality is the main reason for Aβ accumulation, the formation of NFT, and degeneration of synapses in AD. Mitochondrial causative theory utilizes many theoretical liberties. It presumes that the physiologic mechanisms underlying AD and the aging brain are similar. It states that based on the fact that mitochondrial dysfunction in AD is systematic, mitochondrial dysfunction is not enough to represent the effects of neuronal degeneration. Furthermore, the hypothesis of the mitochondrial cascade forecasts that non-Mendelian inheritance is linked to non-autosomal dominant AD. Lastly, it postulates that AD brain mitochondrial abnormality propels amyloidosis, phosphorylation of tau, and cell cycle re-entry. Mitochondrial dysfunction is detected in many AD tissues, which include fibroblasts, platelets, mitochondria, and brain. There are three main defective mitochondrial enzymes involved: α-ketoglutarate dehydrogenase complex, pyruvate dehydrogenase, and cytochrome oxidase. AD brain investigations have revealed a normal concentration of cytochrome oxidase but with an altered structure of the enzymes itself. Oxidative stress and proteasome abnormality have been hypothesised to enhance mitochondrial dysfunction. Moreover, studies involving cytoplasmic hybrids (cybrid) have revealed that mitochondrial DNA (mtDNA) is partly responsible for the decreased cytochrome oxidase in AD.

**COMMONLY USED CHEMICALS TO INDUCE AD-LIKE SYMPTOMS IN RODENTS**

Some of the common chemicals used for modelling AD are scopolamine, streptozotocin, and alcohol, as well as dysregulation of heavy metals, such as aluminum (Al), copper (Cu), zinc (Zn), lead (Pb), and reducing sugar (D-galactose), among others (Tables 1, 2 and 3).

**Aluminum as one of the frequently used heavy metals for induction of cognitive impairment**

Environmental heavy metals are agents that have been well-established to impact the development of the brain through neurotoxicity. Among the commonly used Alzheimerogenic chemicals, heavy metals have been identified to induce high levels of toxicity that is linked with several diseases, including neurodegenerative disorders, following long-term exposure in humans or chronic administration in rodents. A growing body of support has reported the relation between heavy metals and neurodegenerative diseases, including AD and Parkinson’s disease. Heavy metals are generally known to damage the nervous system. Of all the heavy metals, the effect of aluminum on biological systems has been well-reported. Al is an ubiquitously scattered environmental and industrial toxicant associated with anemia, osteomalacia, and hepatic and...
The high amount of Al has been identified in the brain of subjects suffering from AD and causes toxicological effects, including encephalopathy, bone disease, and anemia. Very recently, orally administered Al (300 mg/kg body weight) was reported to induce oxidative stress, cholinergic deficit, and accumulation of $\alpha\beta$ & NFTs in the brain of rats.

Moreover, in the Al-treated group, there are marked histopathological changes and diffuse gliosis accompanied by pericellular edema in the cerebral region, in addition to neuronophagia and loss of neurons. A number of studies have shown that Al neurotoxicity is highly linked with cognitive impairment of AD, via oxidative stress and cholinergic dysfunction. The findings have indicated an upregulation in the expression and activity of acetylcholinesterase (AChE) and malondialdehyde (MDA), but a significant decrease in expression and activity of glutathione-s-transferase (GST), glutathione peroxides (GPX), and glutathione reductase (GR).

Scopolamine-induced AD-like dementia

A growing body of knowledge has established that scopolamine is an anticholinergic drug mostly employed as an approved chemical in pilot studies to cause memory deficit. Administration of scopolamine leads to deficits in visual recognition memory, verbal recall, visuospatial praxis, visuospatial recall psychomotor speed, and visuoperceptual processes. It is one of the most potent and commonly used drugs to prevent motion sickness. Furthermore, researchers have documented that scopolamine non-selectively occludes the adhesion site of ACh muscarinic receptors in the cerebral cortex and results in the unequal discharge of ACh, which annihilates hippocampal neurons and induces learning and memory impairment in mice in a dose-related manner. However, the main effects of scopolamine likely result from blockage of some receptors (M1 and M5) due to their distinct distribution in the brain. Previous studies have also suggested that it may lead to memory and learning deficit in a dose-dependent way. In some instances, ordinary doses of scopolamine led to agitation, confusion, hallucination, paranoid behaviors, delusions, and incoherent speech. Previous studies have indicated there is potential participation of N-methyl-D-aspartate (NMDA) receptor mechanisms of the dorsal hippocampus in memory loss due to scopolamine induction. Currently, histone deacetylase-2 and DNA methyl transferase-1 are important for synaptic plasticity induced by scopolamine after a decrease in memory. Hippocampal administration of scopolamine occludes long-term potentiation and impedes spatial encoding. Furthermore, the injection of scopolamine into the medial septum impedes learning and decreases ACh discharge into the hippocampus, injection of scopolamine in the CA3 area of the hippocampus induces encoding impairments selectively, but memory retrieval in Hebb-William maze was not affected.

Figure 1: Some Alzheimerogenic chemicals. The neurotoxic effects of these chemicals lead to gradual neuronal loss and thereby resulting in neurodegeneration and its associated symptoms.
Indeed, scopolamine has been identified to cause spatial learning and memory deficiencies. Consequently, it leads to the excitation of glycogen synthase kinase-3 beta (GSK-3β), inadequate spine maturation, and the arborization of dendrites connected with alterations in CREC, Homer1, and amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor (AMPA)\textsuperscript{118}. 

**Colchicine-induced AD-like symptoms**

Advances in chemicals used for modelling AD have suggested that colchicines are potential drugs that induce dementia through dysfunctional cholinergic neurons by either inhibiting cholinergic reversal or eroding cholinergic passage cascades\textsuperscript{119,120}. Colchicine induces hippocampal lesions resulting in cognitive impairments and ChAT reduction, suggesting that it can be utilized as a candidate for modelling AD. Colchicine could cause neurotoxicity and memory decline by inhibiting cholinergic pathways, thereby leading to a reduction in the number of cholinergic neurons and subsequently decreasing cholinergic renewal primarily within the hippocampal area of the brain\textsuperscript{121}. Memory impairment seen induced by colchicine may be a result of a decrease in serotonin, dopamine, and norepinephrine within the caudate nucleus, hippocampus, and entire cerebral cortex\textsuperscript{122}.

Furthermore, colchicine was shown to cause the production of protein carbonyls following lipid peroxidation\textsuperscript{123}. Colchicine has also been found to raise cyclooxygenase-1, and 2 (COX-1 and COX-2) expression levels\textsuperscript{124} and ROS generation\textsuperscript{125}. Colchicine raises glutamate/GABA ratio in the cortex\textsuperscript{126} and triggers excitation of MDA receptors that lead to a sharp rise in the influx of Ca\textsuperscript{2+}, therefore resulting in the triggering of enzymes that depend on Ca\textsuperscript{2+} (e.g. phospholipases A\textsubscript{2}, xanthine oxidase, proteases, cyclooxygenases, and protein kinases)\textsuperscript{127}. Intracerebroventricular (ICV) administration of colchicine (7.5 g in 10 L) was found to recapitulate cognitive memory decline in rats\textsuperscript{128} and similarly in mice\textsuperscript{119}. A significant memory deficit was observed two weeks after cognitive induction impairment using colchicine\textsuperscript{119}. Furthermore, 3 g/mice (ICV injection) of colchicine induces spatial memory impairment\textsuperscript{129}. The main advantage of this model is the fact that it causes some symptoms of sporadic Alzheimer’s type of dementia, similar to those found seen in human subjects, like time-variant changes in onset, behavioral, and biological patterns\textsuperscript{123}.

**Streptozotocin-induced AD-like cognitive decline**

Streptozotocin (STZ), a compound derived from glucosamine nitrosourea and found in the strain of *Streptomyces achromogenes*, when administered ICV in rodents\textsuperscript{130}, is known to exert a severe and long-lasting effect on the brain’s cytoarchitecture, biochemistry, metabolism, and functions (such as decreased glucose uptake and energy consumption, oxidative tissue stress, cholinergic differential, and cognitive abilities). STZ is another alkylation agent used in cancer treatment. It has also been found to mimic certain properties of nitrosourea, an anti-cancer agent that has been reported to have hypoglycemic effects in addition to being involved in memory damage\textsuperscript{110}. Induction of neuronal damage and hyperphosphorylation of tau is caused by STZ, resulting in the release of ROS and reactive nitrogen species (RNS)\textsuperscript{131}. Findings revealed that STZ destroys the glycolytic enzyme activity within the brain which eventually results in the lowering of ATP and creatine phosphate concentrations. This destroyed energy system and lowered acetyl CoA synthesis can inhibit cholinergic conductance\textsuperscript{130}. Rats induced by STZ have been reported to demonstrate raised activities of AChE in their brains and decreased ACh. In other studies, STZ has been found to activate Aβ peptide-like aggregates by modifying the GSK alpha/beta\textsuperscript{132}. Furthermore, there is evidence that gene expression associated with the development of glial-derived NF, brain-derived neurotrophic factors (BDNF) and integrin –alpha-M becomes increased by STZ, while expression of genes for NGE-IB and metallothionein 1/2 is down-regulated and eventually results in the modification in apoptosis and cell survival process\textsuperscript{133}. Administration of ICV-STZ resulted in a substantial decrease in memory and learning skills of rats, leading to oxidative stress\textsuperscript{134}. Additionally, ICV administration of STZ (3 mg/kg) in a model of cognitive impairment in rats mimicked the sporadic dementia of AD\textsuperscript{135}. Memory impairment was observed in the rats during the last phase of the experiment using the Morris water maze (MWM) task in order to assess AD-like symptoms. In addition, impaired glucose metabolism, a decrease in cholinergic markers, and oxidative stress were seen in the rats’ brains. Altogether, these long-lasting effects mimicked those seen in AD patients.
Table 1: Studies showing Alzheimerogenic Chemicals

<table>
<thead>
<tr>
<th>S/N</th>
<th>Species</th>
<th>Chemical</th>
<th>Age/weight/route of administration</th>
<th>Behaviour</th>
<th>Biochemical Assay</th>
<th>Histopathology</th>
<th>Ref</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. 1</td>
<td>Rats</td>
<td>Al</td>
<td>150 – 170 g, 3 times a week 50 mg/kg, 90 days Orally</td>
<td>Short-term &amp; long term cognitive disturbance, Slow locomotor activity</td>
<td>↓ AChE, ↓ CAT, GSH</td>
<td>-Neuronal loss, -Vacuolated cytoplasm</td>
<td>136</td>
</tr>
<tr>
<td>1. 2</td>
<td>Female Sprague-Dawley Rat</td>
<td>Al, Cu &amp; Fl</td>
<td>170 – 200 g, 50, 5 &amp; 20 mg/kg, 40 days Orally</td>
<td>Significant learning deficit</td>
<td>↓ GSH, SOD, ↓ GST &amp; GPx, ↑ proinflammatory cytokines, ↑ proinflammatory gene expression, ↑ APP gene expression, ↑ Aβ42 level, ↓ Aβ accumulation, oxidative stress</td>
<td>-Degeneration of pyramidal neurons with pyknotic nuclei, -Swollen neurons &amp; vacuolation, -Apoptotic cells, -Neuronal degeneration with eosinophilic accumulation</td>
<td>137</td>
</tr>
<tr>
<td>1. 3</td>
<td>Rats</td>
<td>Rats AlCl₃</td>
<td>180-200 g, 300 mg/kg, 60 days Orally</td>
<td>Memory impairment, Spatial Learning &amp; memory</td>
<td>↑ AChE activity, ↑ proinflammatory cytokines, ↑ TNF-α, ↑ IL-1β &amp; IL-12, ↑ BDNF mRNA levels, ↓ CAT, GSH, GST &amp; MDA levels in hippocampus</td>
<td>Neuronal loss pyknosis in CA1 &amp; CA3</td>
<td>2</td>
</tr>
<tr>
<td>1. 4</td>
<td>Rats</td>
<td>Rats AlCl₃</td>
<td>250-300 g, 17 mg/kg, 21 days Orally 12–15 weeks old</td>
<td>Impaired cognitive function, Decrease in time to reach food &amp; deteriorated memory</td>
<td>↑ IL-6, ↑ IL-17 neuro-toxicity due to NO &amp; ROS, ↓ AChE activity, ↓ ACh, ↓ BDNF, ↓ DA, ↓ TAC, ↓ Aβ plaques formation</td>
<td>↓ in cells in granular &amp; pukinje layers, -Thin irregular reduction in cell size, -Sparse distributed cells in molecular layer, -Sparingly distributed cells in cortex, -Neurodegeneration in cortex, -DNA damage</td>
<td>138</td>
</tr>
</tbody>
</table>

Table 2: Studies showing Alzheimerogenic Chemicals (Continued)

<table>
<thead>
<tr>
<th>S/N</th>
<th>Species</th>
<th>Chemical</th>
<th>Age/weight/route of administration</th>
<th>Behaviour</th>
<th>Biochemical Assay</th>
<th>Histopathology</th>
<th>Ref</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.5</td>
<td>Rats</td>
<td>AlCl3 + D-gal OG &amp; IP</td>
<td>280-300 g 10 weeks 300 mg/kg 60 mg/kg</td>
<td>Memory and Learning deficits Spent short time in the target quadrant</td>
<td>↑ AChE activity ↑ Protein expression</td>
<td>Neurodegeneration in hippocampal neurons Amyloid-like deposit</td>
<td>103</td>
</tr>
<tr>
<td>1.6</td>
<td>Rats</td>
<td>ICV/STZ</td>
<td>280-300 g 0.5 mg/kg (3-5 weeks) 1 mg/kg (9-11 weeks) 3 mg/kg</td>
<td>Severe impairment in working memory</td>
<td>↓ ChAT mRNA ↓ IR expression</td>
<td>Astrogliosis dark neurons indicating neurodegeneration ↓ Astrocytes in DG, CA1 &amp; neuronal death</td>
<td>139</td>
</tr>
<tr>
<td>1.7</td>
<td>Rats</td>
<td>ICV/STZ</td>
<td>350-400 g 2 mg/kg 3-4 months</td>
<td>Cognitive impairment</td>
<td>↓ Synaptophysin</td>
<td>Neuronal loss Ventricular enlargement p-tau &amp; Aβ peptide accumulation</td>
<td>140</td>
</tr>
<tr>
<td>1.8</td>
<td>Mice</td>
<td>ICV/STZ Single-dose</td>
<td>20-25 g 2 weeks</td>
<td>Learning &amp; memory performance ↓ in mean time spent in a quadrant by MWM Deficit in spatial learning impairment in novelty in seeking behaviour</td>
<td>↓ α-secretase activities ↓ cerebral Aβ42, β-secretase &amp; COX-2</td>
<td>Aβ deposits</td>
<td>141</td>
</tr>
<tr>
<td>1.9</td>
<td>Rats</td>
<td>ICV/STZ</td>
<td>220-25 g 5 µl 3 months</td>
<td>Deficits in spatial learning &amp; memory in MWM passive avoidance task</td>
<td>↑ Oxidative stress ↓ GSH ↑ MDA levels</td>
<td>Aβ deposits Shrunken pyramidal cell layer &amp; organisation Cellular infiltration &amp; congestion Apoptotic cells &amp; neuronal loss</td>
<td>142</td>
</tr>
</tbody>
</table>

Table 3: Studies showing Alzheimerogenic Chemicals (Continued)

<table>
<thead>
<tr>
<th>S/N</th>
<th>Species</th>
<th>Chemical</th>
<th>Age/weight/route of administration</th>
<th>Behaviour</th>
<th>Biochemical Assay</th>
<th>Histopathology</th>
<th>Ref</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.10</td>
<td>Rats</td>
<td>ICV/STZ</td>
<td>300-340 g 3-4 months 30 days</td>
<td>- Memory impairment - Decrease in time spent - In closed arm 0/OFF - Deficits in short-term - Spatial memory seen - Is decrease time spent - On new arm Using Y - Maze - Short-term recognition</td>
<td>Neuro inflammation</td>
<td>↓ Cell propagation ↓ in proliferation of marker Ki-6 &amp; immature neurons DCX in SVZ</td>
<td>143</td>
</tr>
<tr>
<td>1.11</td>
<td>Rats</td>
<td>IP/SCM</td>
<td>150-250 g 20 g/kg</td>
<td>- Memory deficit - ↑ conditional avoidance</td>
<td>↑ MDA ↑ Lipid peroxidation ↓ GSH level ↑ AChE activity</td>
<td>Degeneration of neurons with pyknotic &amp; condensed nuclear Gliosis</td>
<td>144</td>
</tr>
<tr>
<td>1.12</td>
<td>Rats</td>
<td>IP/SCM</td>
<td>200-220 g 1 mg/kg</td>
<td>- Severe memory impairment - (ST &amp; LT in hippocampus) - Delayed latency in MWM - &amp; frontal dependent memory - Task</td>
<td>Occluded cholinergic signals</td>
<td>Altered cortico-hippocampal neurons Retraction process in pyramidal cell Layer Vacuolation of surrounding neutrophils of pyramidal cells &amp; hyperchromatic &amp; shrunken perikaryo Cork-screw shaped apical dendrites</td>
<td>145</td>
</tr>
</tbody>
</table>

Continued on next page
<table>
<thead>
<tr>
<th>S/N</th>
<th>Species</th>
<th>Chemical Route</th>
<th>Age/Weight</th>
<th>Route of Administration</th>
<th>Behaviour</th>
<th>Biochemical Assay</th>
<th>Histopathology</th>
<th>Ref</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.13</td>
<td>Rats</td>
<td>OG/SCM</td>
<td>150-200 g</td>
<td>2.5 mg/kg 1 hour</td>
<td>Memory impairment</td>
<td>↑ AChE activity, ↓ GABA &amp;GSH</td>
<td>Neuronal degeneration Hippocampal Phalomalacia &amp; Oedema in tissue matrix with de-myelination Congestion of blood Capillaries Perivascular Oedema in cortex</td>
<td>146</td>
</tr>
<tr>
<td>1.14</td>
<td>Mice</td>
<td>IP/SCM</td>
<td>20-25 g</td>
<td>1 mg/kg 8 weeks old</td>
<td>Impairment of learning &amp; memory - Impairment of acquisition of ST &amp; LT</td>
<td>↓ mRNA expression, ↑↓ AChE</td>
<td>-</td>
<td>147</td>
</tr>
<tr>
<td>1.15</td>
<td>Mice</td>
<td>IP/SCM</td>
<td>17—24 g</td>
<td>10 mg/kg 7-12 weeks</td>
<td>Impaired memory - Deficits in ambulatory movement - Deficits in social recognition</td>
<td>↑ Cholinergic neurones</td>
<td>-</td>
<td>148</td>
</tr>
<tr>
<td>1.16</td>
<td>Rats</td>
<td>ICV/CLC</td>
<td>200-260 g</td>
<td>7.5 μg in 2.5μl aCSF</td>
<td>Memory loss</td>
<td>↑ TNF-α, ↑ ROS, COX2 Nitrite</td>
<td>-</td>
<td>149</td>
</tr>
<tr>
<td>1.17</td>
<td>Rats</td>
<td>ICV/CLC</td>
<td>180-200 g</td>
<td>15 μl/15 μl aCSF 21 days</td>
<td>Significant memory loss Learning &amp; memory deficits</td>
<td>↓ GSH, SOD, GST ↑ MDA levels Oxidative damage ↑ AChE activity</td>
<td>Destruction of neurons</td>
<td>150</td>
</tr>
<tr>
<td>1.18</td>
<td>Rats</td>
<td>ICV/CLC</td>
<td>180-200 g</td>
<td>15 μl/15 μl aCSF 3 weeks</td>
<td>Cognitive impairment Learning and learning deterioration</td>
<td>↑ MDA level ↔ CAT ↓ GSH ↓ AChE</td>
<td>Neuronal loss</td>
<td>151</td>
</tr>
<tr>
<td>1.19</td>
<td>Rats</td>
<td>ICV/CLC</td>
<td>180-200 g</td>
<td>15 μl/1 rat 3 weeks</td>
<td>Memory impairment Impaired acquisition of spatial navigation task</td>
<td>↓ GSH, Oxidative stress ↑ ROS Aβ peptide deposit in hippocampus</td>
<td>Neuronal damage ↓ hippocampal tissue levels of BDNF Aβ deposits in hippocampus</td>
<td>152</td>
</tr>
</tbody>
</table>

Continued on next page
### Table 3 continued

<table>
<thead>
<tr>
<th>S/N</th>
<th>Species</th>
<th>Chemical</th>
<th>Age/weight/route of administration</th>
<th>Behaviour</th>
<th>Biochemical Assay</th>
<th>Histopathology</th>
<th>Ref</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.20</td>
<td>Rats/ Mice</td>
<td>ICV/ CLC</td>
<td>200-250 g 20-30 g 7.5 μl in 2.5 μl 6-8 weeks old</td>
<td>Memory impairment</td>
<td>↑ TNF-α IL-113</td>
<td>Neurodegeneration</td>
<td>153</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>↑ ROS &amp; nitrite</td>
<td>Plaque formation</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Reduction in the intensity of Nissl granules</td>
<td></td>
</tr>
<tr>
<td>1.21</td>
<td>Rats</td>
<td>IH/OKA</td>
<td>200-320 g 90 days 100 ng 12 days</td>
<td>Decrease in time finding platform Spatial cognitive</td>
<td>↓ Glu synthetase ↓ GSH Oxidative stress</td>
<td>Gliosis Astrogliosis ↓ GFAP expression</td>
<td>154</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Gliosis p-tau-like formation</td>
<td></td>
</tr>
<tr>
<td>1.22</td>
<td>Rats</td>
<td>ICV/OKA</td>
<td>300-380 g 100-200 ng</td>
<td>Spatial cognitive deficit Significant ↓ in time to find platform</td>
<td>↓ GSH Oxidative Stress Tau phosphorylation site at 396</td>
<td>Gliosis</td>
<td>155</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1.23</td>
<td>SD Rats</td>
<td>ICV/OKA</td>
<td>220-250 g 200 ng 13 days</td>
<td>Memory deficit Poor memory performance</td>
<td>↑ MDA &amp; Nitrite ↓ GSH &amp; Lipid peroxidation</td>
<td>Loss of pyramidal Blabbing of cells in the brain &amp; sponginess Synaptic dysfunction</td>
<td>156</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Neuronal damage Nuclear pyknosis Reduced density of Nissl bodies Neurofibrillary degeneration</td>
<td></td>
</tr>
<tr>
<td>1.24</td>
<td>Mice</td>
<td>ICV/OKA</td>
<td>20-22 g 200 ng 2 times 3 days interval</td>
<td></td>
<td>↓ GPx ↑ MDA mitochondrial cells</td>
<td>Neuronal loss</td>
<td>157</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Neuronal loss</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>↓ in microglial cells</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>↓ hippocampal DG cells</td>
<td></td>
</tr>
<tr>
<td>1.25</td>
<td>Mice</td>
<td>OG/Ethanol</td>
<td>18-22 g 12 mL/g Once daily 1st week Twice daily after 1st week</td>
<td>Cognitive impairments Short distance covered during spontaneous movement</td>
<td>↑ TNF-a &amp;IL-8</td>
<td>Neuronal loss</td>
<td>158</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>↓ Glu &amp; GABA Neurotransmitter imbalances</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1.26</td>
<td>SD Rats</td>
<td>OG/Ethanol</td>
<td>257-300 g 5 g/kg Days 2 &amp; 4</td>
<td>Learning &amp; memory deficits</td>
<td>↑ TNF-α in Hippocampus ↔ IL-10 BDNF</td>
<td>Shorter microglia Lack of ED-1 positive cells</td>
<td>159</td>
</tr>
</tbody>
</table>

Continued on next page
<table>
<thead>
<tr>
<th>S/N</th>
<th>Species</th>
<th>Chemical</th>
<th>Age/weight/route of administration</th>
<th>Behaviour</th>
<th>Biochemical Assay</th>
<th>Histopathology</th>
<th>Ref</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.27</td>
<td>Rats</td>
<td>OG/ Ethanol 180-200 g 396-426 g (after long exposure)</td>
<td>Memory impairment</td>
<td>↑ IL-15 gene NSD alter long term exposure</td>
<td>Reduction in the microglia shortening &amp; of processes with brush appearance</td>
<td>160</td>
<td></td>
</tr>
<tr>
<td>1.28</td>
<td>SD Rats</td>
<td>OG/ Ethanol 4.5 mg/kg 200-300 g 21 days</td>
<td></td>
<td>↑ AChE activity</td>
<td>Neuronal death Apoptotic cells Neurodegeneration</td>
<td>161</td>
<td></td>
</tr>
<tr>
<td>1.29</td>
<td>Rats</td>
<td>OG/ Ethanol 4.5 g/kg 170-220 g 21 days</td>
<td>Cognitive impairment ↓ discrimination index in novels object discrimination</td>
<td>↓ AChE activity Oxidative stress</td>
<td>-</td>
<td>162</td>
<td></td>
</tr>
<tr>
<td>1.30</td>
<td>SD Rats</td>
<td>ICV/LPS 2 ul/1min 200-220 g 21 days</td>
<td>-Loss of spatial memory -Reduction in sniffing times -Less platform-cross number</td>
<td>↑ IL-1β in hippocampus ↑ TNF-α &amp; COX-2 ↑ NF-Kb, iNOS</td>
<td>-</td>
<td>163</td>
<td></td>
</tr>
<tr>
<td>1.31</td>
<td>Mice</td>
<td>IH/LPS 40 ug/mouse single admin 18-22 g 7 days</td>
<td>-Learning &amp; memory impairment -Treated mice took longer time to find platform using ↑ MWM -Spontaneous alteration in Y-Maze mRNA</td>
<td>↓ TNT-α, NO &amp; IL-6 Activation of microglia in hippocampus CA1 &amp; DG</td>
<td>Reduction in NeuN stained area of neurons in hippocampus ↓ in number of DCX positive cells</td>
<td>164</td>
<td></td>
</tr>
<tr>
<td>1.32</td>
<td>ICR Mice</td>
<td>IP/LPS 250 ul/kg 7 times Daily</td>
<td>Memory deficit Spent longer time in a target quadrant</td>
<td>↓ IL-1β, IL-6 &amp; TNF-α ↓ GSH/GSSG ↓ COX-2, iNOS ↑ MDA content</td>
<td>Brown coloured labelled (Aβ42) cells in the hippocampus Higher GFAP Iban1-reactive cells</td>
<td>165</td>
<td></td>
</tr>
<tr>
<td>1.33</td>
<td>SD Rats</td>
<td>IP/LPS 250 g 10 mg/kg Single dose 7 —9 days</td>
<td>↑ TNF-α IL-1β &amp; IL-6</td>
<td>Deposits of Aβ plaques P—tau inclusions in the brain</td>
<td>-</td>
<td>166</td>
<td></td>
</tr>
<tr>
<td>S/N</td>
<td>Species</td>
<td>Chemical</td>
<td>Age/weight/route of administration</td>
<td>Behaviour</td>
<td>Biochemical Assay</td>
<td>Histopathology</td>
<td>Ref</td>
</tr>
<tr>
<td>-----</td>
<td>---------</td>
<td>----------</td>
<td>-----------------------------------</td>
<td>-----------</td>
<td>------------------</td>
<td>----------------</td>
<td>-----</td>
</tr>
<tr>
<td>1.34</td>
<td>ICR Rats</td>
<td>IP/LPS</td>
<td>0.25 mg/kg</td>
<td>2 months old</td>
<td>21 days</td>
<td>- Deficits in spatial memory - Decrease in latency</td>
<td>↑ Aβ42 in cortex &amp; hippocampus ↑ β-secretase activity ↑ γ-secretase in Hippocampus &amp; Cortex ↑ iNOS, COX-2 &amp; GFAP</td>
</tr>
<tr>
<td>1.35</td>
<td>SD Rats</td>
<td>SC/NAN3</td>
<td>4—51 mg/kg/day (mini pumps)</td>
<td>300-320 g 31 days</td>
<td>Learning &amp; memory deficits Weaker cognitive performance</td>
<td>↓ ChAT &amp; AChE activity</td>
<td>Pycnotic nerve cells Nerve cell loss Corkscrew-like dendrites Positively stained granules by AT8-positive (tau) granule</td>
</tr>
<tr>
<td>1.36</td>
<td>Rats</td>
<td>IP/AN3</td>
<td>12.5 mg/kg/day</td>
<td>200-250 g 5 days 9 days</td>
<td>-Impairment of learning &amp; memory -Spent more time explore target -quadrant</td>
<td>↓ GSH levels ↑ AChE, Nitrite ↑ TBARS, MPO Cytochrome C NO</td>
<td>Neuronal loss</td>
</tr>
<tr>
<td>1.37</td>
<td>SD Rats</td>
<td>SC/ NAN3</td>
<td>400—425 g 1 mg/kg/h 7 days</td>
<td>-Impairment of learning &amp; memory -Spent more time explore target -quadrant</td>
<td>↓ Cytochrome C ↔ NO</td>
<td>-</td>
<td>170</td>
</tr>
</tbody>
</table>

Ethanol/Alcohol induced AD-like symptoms

Chronic intake of alcohol is associated with many problems including attention deficits, impairment in language and social skills, hyperactivity, motor dysfunction, and learning deficits. Previous studies have shown that ethanol consumption enhances the generation of ROS and results in a decrease of the antioxidants in the brain. Another finding has suggested that ethanol could damage hippocampal and cholinergic neurons with a resultant effect on the sensory-motor system as well as disruption of learning and memory. High ethanol treatment resulted in excessive nitric oxide (NO), which has been found to destruct memory and learning, while higher doses of ethanol disrupted the glutamatergic system and increased GABAergic conveyance in the brain areas that are associated with memory. Ethanol also elevates the level of adenosine, which may, in turn, lead to memory damage and can result in a shorter route by accelerating memory impairment and promoting active, spontaneous motion.

Furthermore, results obtained following the MWM test in mice showed a notable increase in escape latency and total swimming distance, with a sharp drop in cross time. Thus, chronic alcohol administration can significantly affect spatial learning ability and cognition by mice. However, memory impairment caused by prolonged alcohol intake can be observed from the anti-inflammatory activity and from the control of the equilibrium of Glu and GABA. The particular molecular mechanisms still need further investigations, but overall, alcohol can significantly disrupt learning and memory.

Memory deficit induced by excitotoxin

Ibotenic acid is a strong neurotoxin that aggravates signs and pathophysiology analogous to AD. It is a useful model to appreciate drug efficiency in evading AD pathology. It has also been found that intra-hippocampal administration of ibotenic acid (5 μg/μl PBS) produces memory impairment and results in increased AChE activity as well as elevated MDA levels, thereby inducing neuronal toxicity. Bilateral ICV injection of ibotenic acid may elicit AD-like pathology and symptoms. Indeed, a particular study found that ibotenic acid decreased the activity of cholinergic neurons in rats. Many other cholinotoxins and neurotoxins that present AD-like symptoms are kainic acid, quinolinic acid, anti-NGF, NMDA antagonist dizocilpine, and α-amino-3-hydroxy-5-methyl-4-isoxazololepropionic acid (AMPA). Previous studies have reported that intra-hippocampal kainic acid (0.4 μg/2μl) administration led to oxidative damage (revealed by the increase of hippocampal lipid peroxidation, nitrite level, and diminished superoxide dismutase (SOD)). Thus, it is clear that kainic acid activates oxidative damage and memory loss in rats. Stimulation of glutamate receptors, particularly NMDA receptors, in a diseased condition can lead to disrupted ion homeostasis, decrease in energy, neuronal loss, and cell death (excitotoxicity) by an abnormally high concentration of glutamate.

Sodium azide-induced AD-like memory impairment

Sodium azide (NaN₃) is a white crystalline solid that has been reported to be a mitochondrial toxin implicated in the production of lead azide explosive. NaN₃ administration has been known to induce mitochondrial dysfunction and inhibit cytochrome oxidase, a critical mitochondrial enzyme. Cytochrome oxidase is critical in the mitochondrial respiratory chain; its interference impedes mitochondrial complex-IV and decreases ATP levels, which add to metabolic impairment and ROS generation, ultimately producing some sequelae of AD. Neuronal loss in the CA3 area of the hippocampus is one of the essential features used to confirm the induction of AD using minipumps to deliver NaN₃. However, due to high cost, one-time usability and long treatment time, minipumps are unlikely to be useful tools for screening. A new technique was developed to provide an AD-like dementia model by selective cytochrome C complex inhibition using an intraperitoneal injection of NaN₃ in different doses (10-15 mg/kg/day) in rats. The intraperitoneal injection dose-effect-interdependence study employed mitochondrial poison and developed a complex test system to research changes in cognitive functions induced by treatment with NaN₃. It has been shown that NaN₃ administration impairs learning and memory, and increases AChE levels in the brain. NaN₃ was reported to cause oxidative damage that resulted in neuronal cell death. The progressive loss of neurons and necrosis were observed in the cortical and hippocampal areas of treated rats, thereby further indicating the potency of NaN₃. These researchers confirmed that intraperitoneal injection of NaN₃ for 15 days resulted in a comparable level of dementia using implanted osmotic minipumps in rats, ultimately suggesting the involvement of NaN₃ in inducing neurodegenerative disorder.

A growing body of knowledge has reported that oxidative stress is a trigger, as well as one for the development of AD. This review has highlighted the role of excitotoxins and neurotoxins in the progression of AD and highlighted the potential of using minipumps to deliver NaN₃ as a simple and effective method to induce AD-like symptoms in rats.
of the critical molecular changes for AD commencement. Oxidative stress may be caused by inhibition of mitochondrial function. The mitochondrial enzyme, Cytochrome oxidase (COX), has long been established to be predominantly implicated in aerobic energy metabolism and mitochondrial tasks in AD patients. Brains of AD patients have shown some mitochondrial abnormalities, particularly of CoX type. The primary toxic effect of NaN₃ has been identified as decreasing the action of CoX in the mitochondrial electron transport chain.

**LPS-induced AD-like symptoms**

LPS has been known to be used in various experiments, both in vitro and in vivo models of amyloidosis and neuroinflammation. A variety of neurodegenerative diseases, namely AD, Parkinson’s disease, amyotrophic lateral sclerosis, and multiple sclerosis, have been modeled using LPS-induced systemic inflammation (Figure 2). LPS is extracted from the external membrane of gram-negative bacteria. It has been reported as a strong endotoxin with resistivity to degradation by mammalian enzymes, therefore resulting in continual inflammatory stimuli, which produce proinflammatory cytokines. These proinflammatory cytokines stimulate both neuroimmune and neuroendocrine systems that lead to virtually similar feedback formed by behavioral stress. Inflammation has been reported to be crucial in AD pathogenesis. However, the exact mechanisms through which it participates remains to be elucidated. Inflammatory proteins in the blood, two of which are C reactive protein (CRP) and IL6, have been reported to increase several years before the onset of clinical dementia in different studies. Inflammation is one of the factors that cause AD, although the link between infections and AD etiology has been an issue of debate for more than three decades.

Previous studies have indicated that the expression levels of TNF-α, IL-1β, and IL-6 within the hippocampus are upregulated in comparison with those of control following three days of LPS administration. Proinflammatory cytokines have already been found as the critical molecules which modulate immune responses; inability to reverse them during chronic inflammation would increase dyshomeostasis. Moreover, long-standing microglia activation which facilitates inflammatory mediators release, resulting in enhanced oxidative stress and nitrosative stress, is characterized by chronic inflammation.

**Okadaic acid-induced memory impairment**

Okadaic acid (OKA), a major polyether toxin, is a marine microalga product that causes diarrhetic shellfish toxicity. IC injection of OKA has been reported to induce memory decline in rats, therefore making it a valuable model agent to study for anti-dementia drug screening. In terms of mechanism of action, OKA has been found to be a restrictive and modest antagonist of serine/threonine phosphatases 1 and 2A, is associated with short- and long-term memory disruption in rats, and triggers tau hyperphosphorylation (Figure 2) and neuronal cell death both in vivo and in vitro. Previous findings have identified that OKA decreases basal synaptic transmission and inhibits the commencement of synaptic plasticity. Additionally, OKA has been found to augment Ca²⁺ in a cultured hippocampal neuronal cells by ionotropic excitatory amino acid receptors, thereby leading to loss of neurons.

Furthermore, research has demonstrated that OKA triggers the production of ROS in the hippocampus and reduces mitochondrial activity and mitochondrial potency, ultimately resulting in mitochondrial abnormalities in the brain of rats. OKA has been known to inhibit phosphatases and cause hyperphosphorylation of proteins which subsequently leads to neuronal stress and ultimately to neurodegeneration. Previous findings revealed that OKA-mediated memory decline in rats is linked with exacerbated proinflammatory cytokines, such as TNF-α and IL-1, and with iNOS expression and total nitrite in the hippocampus and cortex. Furthermore, infusion (bilateral) of OKA in the hippocampus produced spatial cognitive deficit as a result of raised GFAP expression, decreased GSH, and enhanced protein carbonylation and mitogen-activated protein kinase 38 (p38MAPK). Several kinases, including MAPK, GSK-3β and cyclin-dependent kinase 5 (Cdk5), have been identified to be implicated in the phosphorylation of tau protein at different positions seen in AD hyper-phosphorylated tau. Meanwhile, tau dephosphorylation is catalyzed through phosphatase PP2A and other phosphatases (PP1, 2B, and 5). The precise blocking of PP2A by OKA could result in Alzheimer-like hyperphosphorylation and aggregation of tau in vivo and in vitro. Memory loss due to OKA (intra-hippocampal) injection has been documented to be linked with apparent neuropathological changes, such as the formation of Ab peptide-like structures, helical filament-like phosphorylated tau, and neurodegeneration in the hippocampus. OKA is an essential means for...
Figure 2: Alzheimerogenic chemicals and some mechanisms used to induce AD. The figure showed some insults underlying AD, the chemicals here induced AD-like cognitive impairments due to the individual mechanism of action. Chronic or acute exposure to any of these chemicals by the brain is associated with one or more of the pathophysiology contained in the box (dotted line). Adapted from Lee et al., 2018.
analyzing the cellular mechanisms involved by reversible protein phosphorylation during cell division, signal transduction, and formation of memory. At present, drugs that act by blocking tau phosphorylation are not available. Thus, this suggests that OKA could be a useful replacement tool towards unraveling therapeutic approaches for AD pathology.

CONCLUSION
Several chemicals have been established in order to unravel AD etiology and screen many possible therapeutic agents. This applies especially to aging, Aβ, aluminum, and D-galactose models, among others. Nonetheless, it is worthy to note that none of the available models recapitulates the exact pathology of AD, although every model is known to have its benefits and triggers a few of the pathophysiology linked with AD. Heavy metals, scopolamine, alcohol, and LPS are among the chemicals with proven neurotoxicity and have been used to induce AD-like cognitive impairment in rodents. Each chemical may act via specific mechanisms that differ in order to exacerbate AD pathogenesis. Thus, the dosage, as well as the time in which the chemical is administered in the AD models of rodents, may be higher or sometimes lesser to induce severe disease in human subjects. Importantly, other factors associated with the Alzheimerogenic chemicals are the route of administration, nature, duration (especially), as well as age and gender of the animals tested. This understanding is critical in order to design research that involves chemically-induced cognitive impairment.

ABBREVIATIONS

AChE: acetyl cholinesterase  
ACh: acetylcholine  
ChAT: choline acetyltransferase  
MDA: Melondialdehyde  
SOD: Superoxide dismutase  
iNOS: inducible nitric oxide  
GSH: glutathione  
GPx: glutathione peroxidase  
CAT: catalase  
DA: dopamine  
BDNF: brain derived neurotrophic factors  
NO: nitric oxide  
ROS: reactive oxygen species  
AC: total antioxidant content  
OG: oral gavage  
ICV: intracerebroventricular  
IH: intrahippocampal  
SC: subcutaneous  
SCM: Scopolamine  
STZ: Streptozotocin  
OKA: Okadaic acid  
CLC: Colchicine  
SD: Sprague-Dawley  
IP: intraperitoneal  
†: increase  
↓: decrease  
++, unchanged  
LPS: Lippolyssacharide  
TNF-α: Tumor necrosis factor  
NFTs: neurofibrillary tangles  
COX-2: Cytocrome oxidase  
TBARS: Thiobarbituric acid reactive substance  
MPO: Myeloperoxidase  
GST: Glutathione S-transferase  
GFAP: Glial fibrillary acid protein

CONFLICTS OF INTEREST
Authors disclose none exists.

AUTHORS’ CONTRIBUTIONS
All authors contributed to the design of the research. OM and SMC searched and summarized the data. SJ, MTBH, NHMN and MAMM reviewed and edited the first draft. All authors reviewed, commented and approved the final draft.

ACKNOWLEDGMENTS
The authors would like to acknowledge University Putra Malaysia for sponsoring this project (grant no.GPIPS 9535400).

REFERENCES


